Indre Ceponiene: Major Gaps in Secondary Cardiovascular Prevention Across Europe
Indre Ceponiene, Head of Cardiovascular CT Department at The Hospital of Lithuanian University of Health Sciences Kauno klinikos, shared a post on LinkedIn:
“As a national investigator, I am proud to share the primary results of the EUROASPIRE VI survey presented at the ESC Congress 2026.
The study included 8,590 patients across 27 countries, evaluated a median of 13.2 months after an index cardiovascular event.
It showed profound variation in how well secondary prevention targets are achieved between countries.
Across the cohort, the residual risk burden remained unacceptably high:
- 83percent had LDL C above 1.4 mmol/L
- 60percent had blood pressure above 130/80 mmHg
- 31percent had chronic kidney disease
These findings echo international evidence that lipid and blood pressure targets are frequently not attained after coronary hospitalisation.
For Lithuania, the results are cautiously encouraging and definitely a step forward.
Our 14percent guideline target score places us closer to the international middle and represents the one of the best performances among the participating high risk countries.
Nevertheless, this also means that many patients remain above recommended lipid and blood-pressure targets after a coronary event an important call to further strengthen long term, guideline directed care.
One particularly positive finding is cardiac rehabilitation: 78percent of Lithuanian patients attended rehabilitation, the second highest result among participating countries.
This is an important national strength that should be protected, sustained and further developed.
Participation in cardiac rehabilitation was associated with:
- Better blood pressure control
- Better LDL C and HbA1c target attainment
- Better kidney function
- Significantly greater use of antiplatelets, lipid lowering therapies and beta blockers.
Thanks to our Lithuanian University of Health Sciences Heart Centre Team for devoting their time and effort to participate in this important registry.”
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 16:28Jon Douglas: Imperial College London Review Maps Key Pathways in Autoimmune Thrombosis
-
Sep 5, 2026, 16:21Kelly Anderson: Bilateral Foot Pain and Purple Toes – Spotting Vascular Complications in Polycythemia Vera
-
Sep 5, 2026, 16:16Hazem Abosheaishaa: Beta-Blocker Selection Matters – Multi-Institutional Cohort Insights on PVT and Survival in Cirrhosis
-
Sep 5, 2026, 16:03W. Alberto Sifuentes Giraldo: Why Obstetric Cases Are Missed Under 2023 ACR/EULAR APS Criteria
-
Sep 5, 2026, 15:58Srikanth Nalla: A Case of Saddle Pulmonary Embolism
-
Sep 5, 2026, 15:55COPD-specific Pulmonary Embolism Diagnostic Strategy – Thrombosis and Haemostasis
-
Sep 5, 2026, 15:41Sam Tsimikas on Lp(a) HORIZON Topline Results – What Missed Endpoints Mean for Cardiovascular Risk
-
Sep 5, 2026, 15:32Stefano Garzon: SELUTION DeNovo HBR – Weren’t HBR Patients Supposed to Bleed More with DES?
-
Sep 5, 2026, 15:24Mayer Hany: Recombinant Activated FVII in Spontaneous Intracerebral Hemorrhage